1	A Systematic Review and Meta-analysis for Association of Celiac Disease and Thyroid Disorders
2	Running Title: Association between CD and Thyroid Disorders
3	Zahra Norouzi <sup>1</sup> , Fatemeh Hasani <sup>1</sup> , Sima Besharat <sup>*1</sup> , Hesamaddin Shirzad-Aski <sup>*2</sup> , Somayeh Ghorbani <sup>3</sup> , Masoud Mohammadi <sup>1</sup> , Anahita
4	Yadegari <sup>4</sup> , Ali Kalhori <sup>5</sup>
5	<sup>1</sup> Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
6	<sup>2</sup> Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
7	<sup>3</sup> Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
8	<sup>4</sup> School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ontario, Canada.
9	<sup>5</sup> Department of Food Sciences and Technology, Nutritional Sciences, The Ohio State University, Columbus, Ohio, USA.
10	* Corresponding Author
11	Fatemeh Hasani, fatemehhassani2001@gmail.com
12	These authors contributed equally to this work.
13	
14	
15	
16	
17	
18	
19	
20	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
21	
22	
23	

## 31 Abbreviations

- 32 CD: Celiac disease
- 33 OR: Odds ratio
- 34 CI: Confidence interval
- 35 ATD: Autoimmune thyroid disease
- 36 TPO: Thyroid peroxidase
- 37 TG: Thyroglobulin
- 38 TSH: Thyroid-stimulating hormone
- 39 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 40 RR: Risk ratio
- 41 HR: Hazard ratio
- 42 NOS: Newcastle-Ottawa Scale
- 43 CTLA-4: Cytotoxic T lymphocytes is related to antigen 4

44

- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53

58

## 59 Abstract

60	It is probable that people who have celiac disease (CD) are more likely to have thyroid disorders. A comprehensive systematic review and meta-
61	analysis were conducted to assess the link between thyroid disorders and CD. Articles were selected from PubMed, Web of Science, Scopus, Ovid,
62	Embase, Cochrane, ProQuest, and Wiley from February 2022 and earlier. A meta-analysis was conducted to evaluate the outcomes, using odds
63	ratios (ORs) and corresponding 95% confidence intervals (95% CIs). The meta-analysis comprised 31 articles with 3310256 participants including
64	101253 individuals with thyroid disorders. Overall, the frequency of thyroid disease was notably higher in patients with CD compared to the
65	control groups (OR: 3.06, 95% CI: 2.51 – 3.72, P<0.001). The findings of our meta-analysis support the notion that patients with CD are more
66	likely to have autoimmune thyroid disease (ATD) and other thyroid disorders than the control group, thus indicating that regular screening for
67	thyroid disease is necessary for CD patients. Further cohort research is required to investigate the relationship between thyroid disorders and CD.
68	Key words: Celiac disease, thyroid, autoimmune thyroid disease, Thyroid Diseases
69	
70	
71	
72	
73	
74	
75	
70	
76	
77	
78	
79	
80	
81	
82	
83	

### 90 Introduction

91 Celiac disease (CD) is an inflammatory autoimmune disorder of the upper small intestine. The disease triggered by gluten-containing food and 92 environmental factors in genetically predisposed patients with the HLA-DQ2 and HLA-DQ8 (1). It affects approximately 1% of the global 93 population (2).

CD patients are considered to have more autoimmune diseases than general population (3). One of the most frequent autoimmune conditions related to CD is autoimmune thyroid disease (ATD). ATD is a group of inflammatory disorders that affect the thyroid gland. The two most common forms of ATD are Graves' disease and Hashimoto's thyroiditis (4). These conditions are characterized by the presence of antibodies such as antithyroid peroxidase (TPO), anti-thyroglobulin (TG), and anti-thyroid-stimulating hormone (TSH) receptor antibodies (5). The risk for the development of these diseases is higher among women compared to men and it also increases with age (6, 7).

99 Graves' disease is the most frequent cause of hyperthyroidism. This disorder is characterized by an autoimmune reaction against thyroid antigens, 100 which leads to secretion of anti-TSH receptor autoantibodies by B cells. These autoantibodies bind to the TSH receptors and chronically stimulate 101 them, leading to chronical secretion of thyroid hormones and thyrotoxicosis (6). On the other hand, Hashimoto's thyroiditis can cause 102 hypothyroidism and is clinically characterized by anti-TPO and anti-TG antibodies. In Hashimoto's thyroiditis, increased infiltration of B and T 103 cells into the thyroid gland causes destruction of follicular cells responsible for the production of thyroid hormones, resulting in hypothyroidism 104 (7).

105 Although the precise reason for the co-occurrence of celiac disease and thyroid disorders is not yet fully understood, several theories have been 106 suggested. These include genetic predisposition, similar cytokine pathways involved in both disease progression, and impaired absorption of key 107 nutrients due to changes in gut permeability. Such factors may contribute to the higher incidence of these conditions occurring together (8).

There are several studies that showed this co-occurrence connection. In a cross-sectional study conducted on 288 CD patients, Baharvand et al. reported that thyroid disease was four times more prevalent in CD patients than in controls (9). Also, Norström, in a study of 335 children with CD, claimed that the risk of thyroid dysfunction associated with thyroid autoimmunity is higher for the CD patients than the healthy control (10). Obaid et al. also investigated 86 CD patients in Iraq from 2018 until 2020. The findings of the study showed a strong association between CD and ATDs (4). In addition, Bibbò et al. found a significant association between Hashimoto thyroiditis and CD, as the most prevalent autoimmune disease in CD patients than controls. (24.3% vs. 10%) (11).

In 2016, Sun et al. conducted a systematic review and meta-analysis comprising of 13 articles with a total of 15,629 CD cases and 79,342 controls. They discovered that the prevalence of thyroid disease was significantly higher in individuals with CD than in the control groups. The odds ratio (OR) was calculated to be 3.08 with a 95% confidence interval (CI) ranging from 2.67-3.56, indicating statistical significance with a P-value of less than 0.001. Interestingly, the analysis revealed that there was no significant difference in the OR between the groups that underwent gluten treatment and these who did not, with an OR of 1.08 and a 05% (CI range of 0.61, 1.02 (P=0.786)). These findings suggest that individuals with CD

- treatment and those who did not, with an OR of 1.08 and a 95% CI range of 0.61-1.92 (P=0.786). These findings suggest that individuals with CD
- are more likely to develop thyroid disorders and therefore should undergo regular screening for thyroid disease. (12).
- 120 However, there is still a need for a comprehensive and systematic review of the available literature to evaluate this association accurately.
- 121 Therefore, and to clarify more, we did a new systematic review aimed at evaluating the incidence of thyroid disease in patients with CD after 5
- 122 years of the previous meta-analysis study and using 8 different databases for a thorough search. In addition to this primary objective, the study
- aims to identify any gaps in the existing literature, such as variations in study design and methodological limitations that may affect the validity
- of the results. By highlighting these gaps, the study can provide insights into future research directions and suggest ways to address these limitations

4

125 effectively.

#### **Materials and Methods** 126

#### **Eligibility Criteria** 127

128 We designed this study based on the methodology of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (13). The registration number in the International prospective register of systematic reviews (PROSPERO) is CRD42021277901 129 (Available: https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID=277901) 130

#### Inclusion/exclusion criteria 131

132 Studies meeting the following criteria were included: 1) human case-control, cohort, and cross-sectional studies reporting on the relationship between thyroid disorders and CD, 2) Reporting of at least one variable showing relative risk effect sizes including risk ratio (RR), odds ratio 133 (OR), and hazard ratio (HR) in both case and control groups. The diagnosis of thyroid disorders in included studies should have been confirmed 134 by serology tests and clinical signs and symptoms. Furthermore, the confirmation of CD should have been based on endoscopy findings, biopsy 135 results, serology tests, and/or HLA DQ2/DQ8 genotyping. Studies that did not include any of this information (including animal studies) were 136 excluded from further analysis. 137

#### 138 **Categories of thyroid disorders:**

Based on a textbook (14) and data extracted from previous original articles, we used four main categories of thyroid disorders for subgroup analysis 139 including hypothyroidism, hyperthyroidism, ATD, and thyroiditis. ATD also had three subcategories including Graves' disease, Hashimoto's 140 thyroiditis, and autoimmune hypothyroidism. Some original articles had an emphasis on coexistent hypothyroidism and autoimmunity, but other 141 142 studies just reported the term ATD; therefore, the association of CD and autoimmune hypothyroidism was also evaluated in the articles that 143 clarified it separately as a subcategory of ATD patients.

Some articles also evaluated and reported the positivity of TPO antibodies and TG antibodies. We extracted and included them in both total and 144 separate analyses. 145

#### **Information Sources and Search Strategy** 146

On 28 February 2022, we conducted our systematic search in the following databases to identify relevant articles: PubMed, Web of Science, 147 148 Scopus, Ovid, Embase, Cochrane, ProQuest, and Wiley. Thorough a three-step process our search keywords and search syntax were designed. First, we extracted the concepts needed for the search following PICO analysis in proportion to the research topic. To accomplish maximum 149 comprehensiveness to recover concepts, we extracted and inserted synonyms, abbreviations, related terms, UK / US spellings singular / plural 150 forms of words, and thesaurus terms in our search syntax. We used the thesaurus MeSH and Emtree for completing keywords. Furthermore, 151 152 thematic searches on databases were performed. Finally, preparatory search was conducted and related keywords of main articles in this subject were analyzed. We also enriched and completed the vocabulary. Consequently, the baseline syntax was Thyroid AND (Celiac OR coeliac OR 153

- Gluten Enteropath\* OR Sprue). Complete search strategies on each database are explained in Supplementary 1. Third, two authors hand-scanned 154
- the manual reference lists of all studies and relevant systematic reviews to avoid any missing. We also tracked citation for all the included articles. 155

#### Supplementary 1. 156

Database	Syntax									Results
PubMed	((Celiac[Title/Abstract]	OR	coeliac[Title/Abstract]	OR	Gluten	Enteropath*[Title/Abstract]	OR	Sprue[Title/Abstract])	AND	837
Publyleu	(Thyroid[Title/Abstract]			837						

Web	of	TOPIC: (Thyroid AND (Celiac OR coeliac OR Gluten Enteropath* OR Sprue))	70.4
Science		Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI.	794
Scopus		(TITLE-ABS-KEY (celiac OR coeliac OR (gluten AND enteropath*) OR sprue) AND TITLE-ABS-KEY (thyroid))	1,249
Embase		((celiac:ti,ab,kw OR coeliac:ti,ab,kw OR 'gluten enteropath*':ti,ab,kw OR spure:ti,ab,kw) AND thyroid:ti,ab,kw) OR ('thyroid disease'/exp AND 'celiac disease'/exp)	3,203
Cochrane		Celiac OR coeliac OR Gluten Enteropath* OR Sprue in Title Abstract Keyword AND Thyroid in Title Abstract Keyword	39
ProQuest		(ab(Celiac OR coeliac OR Gluten Enteropath* OR Sprue) AND ab(Thyroid)) OR (su(Celiac OR coeliac OR Gluten Enteropath* OR Sprue) AND su(Thyroid))	130
Wiley		"Thyroid AND (Celiac OR coeliac OR Gluten Enteropath* OR Sprue)" in Abstract	50
Ovid		((Celiac or coeliac or Gluten Enteropathy or Sprue) and Thyroid).ab.	2
Total = 630	4		

#### 157

#### 158 Quality and risk of bias assessment

To eliminate duplicates and sift through the studies, all articles gathered from the databases were imported into Endnote software (Version X9; 159 Thompson Reuters Corporation, Toronto, ON, Canada). Initially, screening was carried out by assessing the titles and abstracts to determine the 160 eligible articles. Two reviewers (A.Y. and A.K.) independently reviewed the chosen full-texts to classify them into three groups: relevant, 161 irrelevant, and unsure. A third supervisor reviewer (H.S.) resolved any discrepancies. Two independent reviewers (Z.N. and F.H.) evaluated the 162 quality and risk of bias assessment of the eligible articles, using an adapted version of the Newcastle-Ottawa Scale (NOS) form specifically 163 designed for case-control studies. (15). The selected studies were then divided into three groups: poor, fair, and good; according to a score obtained 164 from the selection, comparability, and outcome/exposure categories. This score ranged from zero to eight. In case of any disagreements between 165 166 the two reviewers, a third reviewer (S.B.) was brought in to resolve the issue.

167

#### **Data extraction** 168

Four authors (Z.N, F.H, A.K, and A.Y) extracted the data from each paper based on the list of required variables. We divided the data into three 169 categories: general information, risk of bias assessment, and study setting. The general information category included the first author's names, 170 year of publication, country, and type of study. The risk of bias assessment category focused on assessing the risk of bias in each study. The study 171 setting category included study duration, sample size, total population recruited in each study, age group and age range, sex, the definition of CD, 172 173 source of the data, diagnostic methods, each thyroid disorder, P-value, and the ethical approval. To fix missing items or providing additional necessary data, we sent an e-mail to the corresponding authors of those articles, if possible. 174

#### Data synthesis and analysis 175

We used STATA software, version 12, to calculate pooled OR and its corresponding 95% CIs for each study related to the chance of developing 176

- thyroid disease in patients with CD. The combined OR was presented in a forest plot. Heterogeneity among studies was measured using the Q 177
- Cochrane test and I<sup>2</sup> index. A value less than 50% was considered moderate heterogeneity, while a value above 50% was considered severe 178
- heterogeneity. According to the existence of heterogeneity in the methodology of the studies, at moderate level of heterogeneity, fixed-effect model 179
- was used and at severe levels of heterogeneity, random-effect model was used to combine data in meta-analysis. For finding the cause(s) of 180
- 181 heterogeneity, and to investigate the effect of the type of studies and their quality on the research results subgroup and sensitivity analysis was
- used. Subgroup analysis evaluated factors including the thyroid outcome, type of study, and the risk of bias assessment. In order to evaluate for 182
- the presence of any potential publication bias, Begg's and Egger's tests were performed to assess asymmetry in the funnel plot. A P-value of less 183

- than 0.05 was deemed to be significant. To further investigate the impact of individual studies on the overall pooled OR, a sensitivity analysis
- 185 known as the one-out remove method was utilized. Because two different populations in two different time periods were reported in the Grode et
- al., 2018 study (3), the data of this study was included separately in the analysis, as data I and II.

## 187 **Results**

### **188** Search results

In our primary search, 6304 papers were found in the mentioned databases. After removing duplicates, 4186 citations remained for the title and abstract screening. Based on the inclusion and exclusion criteria, 4114 papers were excluded and 72 full-text articles were used for screening. Out

of the available full-text studies, 31 were deemed eligible and included in both the systematic review and meta-analysis. The reasons for excluding

192 other full-text studies are listed in Figure 1.

193 Figure 1. The process of study selection.

## 194 Characteristics of the included articles

Table 1 shows the detailed description of key characteristics for the 31 included studies. There were 3310256 participants in total, of these, 101253 were in the thyroid group and 3209003 were in the non-thyroid group. Among the studies, Nafeesa et al. had the highest study population with 2426224 participants, including 6506 cases and 2419718 controls (16). All studies were published between 1998 and 2022; furthermore, the data of studies were from the Europe and Asia continents, as well as the USA. In 47.06% of the studies, the thyroid was defined as autoimmune. As a results, the NOS assessment showed that only 67.74% of the studies had good quality.

First Author	Year	Country	Type of study	Definition of CD	Thyroid Outcome	Risk of bias assessment	Case- number	Control number
Snook	1989	England	Case-control	Medical record	Hypothyroidism & Hyperthyrodism	P <sup>a</sup>	148	300
Sategna- Guidetti	1998	Italy	Case-control	Serology & endoscopy	ATD <sup>b</sup>	G °	185	170
Velluzzi	1998	Italy	Case-control	Serology & endoscopy	TPO <sup>d</sup> -Ab <sup>e</sup>	G	47	91
Kowalska	2000	Poland	Case-control	IgA-EmA test	Antithyroid antibodies (TMA <sup>g</sup> and/or ATG <sup>h</sup> and/or anti-TPO)	G	34	28
Toscano	2000	Italy	Case-control	Endoscopy	TPOAbs	F <sup>i</sup>	44	40
Ventura	2000	Italy	Case-control	Serology & endoscopy	TPOAbs	G	90	90
Hakanen	2001	Finland	Case-control	Unknown	ATD & Autoimmune hypothyroidism & Subclinical autoimmune thyroiditis & Graves' disease	G	79	184
Sategna- Guidetti	2001	Italy	Case-control and prospective cohort	Serology & endoscopy	ATD	G	422	605
Ansaldi	2003	Italy	Case-control and prospective cohort	Endoscopy	ATD	G	343	199
da Rosa Utiyama	2005	Brazil	Case-control	Clinical criteria & endoscopy & serology	thyroid microsome antibody positivity	F	76	97
Selimoglu	2005	Turkey	Case-control	Serology & endoscopy	Hypothyroidism & Hyperthyroidism & positive for thyroid microsome antibodies &	G	77	40

200 **Table 1.** Main characteristics of the included studies in the meta-analysis on the thyroid disorders infection and celiac disease (CD)

					positive for antithyroglobulin antibodies			
Guariso	2007	Italy	Cohort		Hashimoto's thyroiditis & ATD	G	267	220
Elfstrom	2008	Sweden	Case-control and prospective cohort	Medical record	Hypothyroidism & Thyroiditis & Hyperthyrodism	Р	14021	68068
Naiyer	2008	US	Case-control	Serology & endoscopy	TPO-Ab, TG-Ab	G	40	40
Neuhause n	2008	US	Case-control and prospective cohort	Serology & endoscopy	Hypothyroidism	F	408	1272
Toumi	2008	Tunisia	Case-control and prospective cohort	Serology & endoscopy	TG-Ab, TPO-Ab, TRAb	G	104	189
Caglar	2009	Turkey	Cross-sectional	Endoscopy &/or serology	anti-TPO positivity & anti-TG positivity	G	31	29
Carlsson	2009	Sweden	Prospective cohort	Serology	TPO Ab positivity	G	207	1151
Garud	2009	USA	Case-control	Medical record	ATD	Р	600	200
Meloni	2009	Italy	Case-control and prospective cohort	Serology & endoscopy	ATD	G	324	8040
Diamanti	2011	Italy	Case-control and prospective cohort	Serology & endoscopy	ATD	G	545	622
Ludvigsso n	2011	Sweden	Case-control and prospective cohort	Endoscopy	ATD	F	7843	38966
Elli	2012	Italy	Case-control	Anti-tTG <sup>j</sup> Ab test & Positive response to GFD <sup>k</sup>	Hashimoto thyroiditis and Grave's disease	G	1015	848606
Ban	2014	UK	Population- based cohort	Medical record	Thyroid disorders	Р	1880	560452
Dhalwani	2014	UK	Cohort	Medical record	Thyroid disorders	Р	6506	2419718
Schuppan	2014	Germany	Case-control	Serological and genetic investigations	ATD	Р	101	132
van der Pals	2014	Sweden	Case-control and prospective cohort	Serology & endoscopy	TPO Abs	G	335	1695
Canova	2016	Italy	Prospective matched cohort	Endoscopy & hospital admission & copayment exemption	Autoimmune hypothyroidism & hyperthyroidism	G	1215	6075
Bibbò	2017	Italy	Case-control	Serology & endoscopy	Hashimoto thyroiditis	G	255	250
Grode I	2018	Denmark	Nation-wide population- based study	Medical record	Graves' disease	G	4171	43774
Grode II	2018	Denmark	Nation-wide population- based study	Medical record	Graves' disease	G	10285	104928
Norström	2018	Sweden USA	Case-control Population	Serology Medical record	TPO Abs Hashimoto	G G	<u> </u>	1665 498
Khan	2019	USA	Population- based studie	wedical record	Hashimoto thyroiditis & Grave disease	U	249	498
Baharvand	2020	Iran	Comparative cross-sectional	Serology & endoscopy	Hypothyroidism & Hyperthyroidism & TPO Abs	Р	288	250
Tiberti	2020	Italy	Case-control	Serology & endoscopy	TPO Abs	Р	92	237

A: Poor; B: Autoimmune thyroid disease; C: Good; D: Thyroid peroxidase antibody; E: Antibody; F: IgA-endomysial antibodies; G: Thyroid
microsomal autoantibodies; H: Anti thyroglobulin antibodies; I: fair; J: tissue transglutaminase; K: Gluten-free diet

#### 203

- The meta-analysis demonstrated that there is a significant relationship between CD and thyroid disorders (pooled OR: 3.06; 95% CI: 2.51 3.72; 204
- $P \le 0.001$ ). Forest plot of the frequency of thyroid disorders in CD patients compared with the control group is shown in Figure 2. 205
- **Figure 2.** Forest Plot illustrating the strong association between Celiac Disease (CD) and thyroid disorders (p < 0.001, pooled OR: 3.06; 95% CI: 206
- 2.51 3.72). 207
- Subgroup analysis 208
- 209 To assess the heterogeneity of the studies, we conducted multiple subgroup analyses based on three factors: types of thyroid disorders, types of
- studies, and quality of studies. The amount of heterogeneity did not change significantly within the subgroup analyses, therefore they cannot be a 210
- source of the heterogeneity. As shown in figure 3, In the subgroup analysis by study type, cross-sectional studies had a lower pooled OR than case-211
- control and cohort studies (OR: 2.04 vs OR: 3.09 and OR: 3.48, respectively). 212
- Figure 3. Demonstration of subgroup analyses based on type of study. 213
- Based on the NOS assessment, most studies had good scores. The pooled OR for fair studies were higher than poor and good studies (OR: 5.36 vs 214
- OR 2.98 and OR: 2.76 respectively). 215
- Figure 4. Subgroup analysis based on Newcastle-Ottawa Scale (NOS) assessment. 216
- Furthermore, the analysis showed a significant relationship between CD and ATD (OR: 2.96, CI: 2.32 3.78, P  $\leq 0.001$ ). (Figure 5). 217
- Figure 5. Subgroup analysis based on autoimmune thyroid disease (ATD) and other thyroid disorders. 218
- 219
- Random effects meta-analysis was conduct for interaction in planned subgroups and adjust common effects (Figure 6). 220
- 221 Figure 6. Random effects of all 31 articles.
- **Publication bias** 222
- The results of Begg's and Egger's tests indicate that the funnel plot does not exhibit significant asymmetry, suggesting the absence of publication 223
- bias in the data. This inference is supported by the p-values obtained from Begg's test (0.75) and Egger's test (0.61) (Figure 7). 224
- Figure 7. Begg's test (p = 0.75) and Egger's test (p = 0.61) results confirm the absence of significant publication bias. 225
- **Discussion:** 226
- 227 To evaluate the risk of thyroid disorders in patients with CD, several case-control and cohort studies have been conducted or are currently
- underway. However, these studies have varying methodologies and sample sizes, and their results are inconclusive. To address this issue, a 228
- systematic review and meta-analysis was conducted to combine all relevant studies and establish strong evidence of any association between CD 229
- and thyroid disorders. After analyzing the findings of 31 studies, we have demonstrated that individuals with CD are at a significantly higher risk 230
- of developing thyroid disorders compared to those in the control population. In fact, the risk is found to be 3.06 times greater for CD patients. 231
- The pathophysiologic reason why thyroid disorder is more common with CD are still under discussion and are not well known. Regarding that, 232
- there are several suggested mechanisms. One of them is related to genetic factors. Studies have shown that human leukocyte antigen (HLA) is 233
- overexpressed in celiac disease. Specifically, HLA-DQ2 and DQ8 have been found to be associated with ATDs, particularly Hashimoto's 234
- thyroiditis. A meta-analysis conducted on this topic revealed that Hashimoto's thyroiditis was more than three times as prevalent in CD patients 235

compared to those without CD. The gene that encodes cytotoxic T lymphocytes is related to antigen 4 (CTLA-4) and ATD. CTLA-4 is located in 236 the HLA region and is also associated with CD, therefore can have a strong connection with thyroid autoimmune diseases (17, 18, 19). 237 238 In CD, patients suffer from malabsorption of nutrients such as iron, selenium, and vitamin D, due to chronic inflammation and villous atrophy. Iron deficiency worsens thyroid dysfunction due to the decreased activity of the heme-dependent TPO, which relates to ATD (e.g., Hashimoto's 239 thyroiditis and Graves' disease) (20). Another involved mechanism is the deficiency of selenium. This deficiency can modulate the expression of 240 selenium proteins, resulting in the inflammation and mucosal damage. Selenium deficiency can negatively impact thyroid function, since selenium 241 proteins act as antioxidants and regulate redox status and thyroid hormone metabolism in thyrocytes. The selenium proteins are also involved in 242 cell growth and apoptosis (21). The mechanism related to vitamin D deficiency and thyroid disorder can be explained as follows: due to vitamin 243 D deficiency, the suppression of T cells is disrupted, resulting in an increase in the release of inflammatory cytokines. This leads to the destruction 244 of thyroid tissue and ATD (22). 245 Additionally, tTG-2 IgA antibodies have also been proven to react with thyroid tissue, which may contribute to thyroid disease in CD. As Naiyer 246 et Al. observed a positive relation between tTG-2 IgA and anti-TPO antibody titers, which indicated the relationship between CD and the presence 247 248 of organ-specific antibodies against thyroid tissue (23). 249 A meta-analysis study conducted in 2016 found that thyroid disorders are three times more prevalent among CD patients compared to those in the control group (OR 3.08, 95% CI 2.67-3.56; P<0.001). In their subgroup analysis for hyperthyroidism by three original articles, they demonstrated 250 that hyperthyroidism has no significant association with CD. However, when a subgroup analysis was conducted using five articles in the present 251 study, it revealed that CD patients have a two-fold risk of developing hyperthyroidism, similar to the impact of the other types of thyroid disorders. 252 On the other hand, our subgroup analysis for hypothyroidism was consistent with the last meta-analysis. The evaluation revealed that the occurrence 253 of hypothyroidism in CD patients was significantly higher when compared to individuals in the control groups (OR 3.38, 95% CI 2.73–4.20, 254 P<0.001) (12). 255 After the final search, we reached 18 articles more than the last systematic article. According to new articles and additional data, the categories of 256 257 thyroid disorders were increased in our study and we analyze them in separate subgroups to reach their specific OR. We also, analyzed the studies according to groups of the quality of the studies based on NOS assessment and types of studies; to determine the possible discrepancies. 258 Fortunately, no discrepancies were detected. Finally, all subgroup analyses demonstrated a strong effect of CD on the occurrence of different 259 260 thyroid disorders.

However, there are some limitations in this study. Some original articles specified that the patients had euthyroid autoimmune disease or autoimmune hypothyroidism, but other articles did not mention that. We suggest for future original articles to distinguish the type of autoimmunity. The other limitation is that low number of studies from Asia, and lack of researches from Africa, South America, and Oceania. So that, the results more emphasize the population in America and Europe. Evaluating other ethnicities is helpful for further studies.

265 **Conclusions**:

- 266 Our systematic review and meta-analysis of 34 original articles included 102545 CD patients show that they are at three to four-fold risk of thyroid
- disorders, especially autoimmune hypothyroidism. We suggest that a design of a cohort study with large sample size of CD patients for a long-
- time follow-up to evaluate any possible thyroid disorders. Furthermore, based on the findings, it is essential to conduct routine screening for thyroid
- 269 disorders in individuals with CD.
- 270 Acknowledgements
- 271 Not applicable.
- 272 Authors' contributions

- 273 Z.N: supervise the project; data extraction; drafting of the article. F.H: helped supervise the project; data extraction; drafting of the article. S.B:
- conception and design; revision of the article. H.Sh: supervise the project; review screening the articles. S.Gh: data analysis; revision of the
- article. A.Y: screening the articles; data extraction. M.M: search strategy and writing syntax; revision of the article. A.K: screening the articles;
- ata extraction. All authors discussed the results and contributed to the final manuscript.

## 277 Funding

278 Not applicable.

## 279 Availability of data and materials

280 All data generated or analyzed during this study are available.

## 281 **Declarations**

- 282 Ethics approval and consent to participate
- 283 Not applicable.
- 284 Consent for publication
- Not applicable.

## 286 Competing interests

- 287 The authors declare no competing interests.
- 288
- 289
- 290
- 291
- 292
- 293
- 294
- 295
- 296
- 297
- 298
- 299


300				
301				
302				
303				
304				
305				
306				

307	Refre	ences
308		
309	1.	Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr. 2008;55(1):349-65.
310	2.	Mearns ES, Taylor A, Boulanger T, Craig KJ, Gerber M, Leffler DA, et al. Systematic literature review of the economic burden of celiac disease.
311	Pharm	nacoeconomics. 2019;37(1):45-61.
312	3.	Grode L, Bech BH, Jensen TM, Humaidan P, Agerholm IE, Plana-Ripoll O, et al. Prevalence, incidence, and autoimmune comorbidities of celiac disease:
313	a natio	on-wide, population-based study in Denmark from 1977 to 2016. Eur J Gastroenterol Hepatol. 2018;30(1):83-91.
314	4.	Obaid KH, Murshd MM, Ali NH. Cd Coexist With Autoimmune Thyroid Diseases. EJMCM. 2020;7(9):682-6.
315	5.	McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252-65.
316	6.	Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves' disease: epidemiology, genetic and environmental risk factors and viruses.
317	Best P	Pract. Res. Clin. Endocrinol. Metab. 2020;34(1):101387.
318	7.	Ralli M, Angeletti D, Fiore M, D'Aguanno V, Lambiase A, Artico M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic
319	proto	cols, therapeutic strategies, and potential malignant transformation. Autoimmun. Rev. 2020:102649.
320	8.	Starchl C, Scherkl M, Amrein K. Celiac Disease and the Thyroid: Highlighting the Roles of Vitamin D and Iron. Nutrients. 2021;13(6):1755.
321	9.	Hormozi M, Aaliehpour A. Comparison of thyroid disease prevalence in patients with celiac disease and controls. GHFBB. 2019.
322	10.	Norström F, Van Der Pals M, Myléus A, Hammarroth S, Högberg L, Isaksson A, et al. Impact of Thyroid Autoimmunity on Thyroid Function in 12-
323	year-c	old Children With Celiac Disease. J. Pediatr. Gastroenterol. Nutr. 2018;67(1):64-8.
324	11.	Bibbò S, Pes GM, Usai-Satta P, Salis R, Soro S, Colosso BMQ, et al. Chronic autoimmune disorders are increased in coeliac disease: A case-control
325	study.	Medicine. 2017;96(47).
326	12.	Sun X, Lu L, Yang R, Li Y, Shan L, Wang Y. Increased Incidence of Thyroid Disease in Patients with Celiac Disease: A Systematic Review and Meta-
327	Analys	sis. PLoS One. 2016;11(12):e0168708.
328	13.	Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.
329	2009;6	6(7):e1000097.
330	14.	Nyström E, Berg GEB, Jansson SKG, Torring O, Valdemarsson SV. Springer Berlin Heidelberg; 2011.
331	15.	Scale N-O. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of
332	nonra	ndomised studies in meta-analyses. 2014.
333	16.	Dhalwani NN, West J, Sultan AA, Ban L, Tata LJ. Women With Celiac Disease Present With Fertility Problems No More Often Than Women in the
334	Gener	al Population. Gastroenterology. 2014;147(6):1267-74.e1.
335	17.	Hunt KA, McGovern DP, Kumar PJ, Ghosh S, Travis SP, Walters JR, et al. A common CTLA4 haplotype associated with coeliac disease. Eur. J. Hum.
336	Genet	. 2005;13(4):440-4.

DA C. Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol. 2003;31:21-36. 337 18.

- King A, Moodie S, Fraser J, Curtis D, Reid E, Dearlove A, et al. Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur. 338 19.
- J. Immunol. 2003;30(6):427-32. 339
- 20. O'Kane SM, Mulhern MS, Pourshahidi LK, Strain J, Yeates AJ. Micronutrients, iodine status and concentrations of thyroid hormones: a systematic 340
- review. Nutr. Rev. 2018;76(6):418-31. 341
- 342 21. Sanmartín C, Plano D, Sharma AK, Palop JA. Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy. Int J Mol
- Sci. 2012;13(8):9649-72. 343
- 344 22. Mackawy AM, Al-Ayed BM, Al-Rashidi BM. Vitamin d deficiency and its association with thyroid disease. Int J Health Sci (Qassim). 2013;7(3):267-75.

- 345 23. Naiyer AJ, Shah J, Hernandez L, Kim S-Y, Ciaccio EJ, Cheng J, et al. Tissue transglutaminase antibodies in individuals with celiac disease bind to thyroid
- follicles and extracellular matrix and may contribute to thyroid dysfunction. Thyroid. 2008;18(11):1171-8.



	с	ase	C	ontrol		OR	Weight
Study	Yes	No	Yes	No		with 95% CI	(%)
Sategna-Guidetti et al, 1998	38	147	19	151		2.05 [ 1.13, 3.73]	3.38
Velluzzi et al, 1998	14	33	9	82		3.87 [ 1.53, 9.79]	2.33
Kowalska et al, 2000	14	20	2	26		9.10 [ 1.85, 44.72]	1.16
Ventura et al, 2000	13	77	4	86		3.63 [ 1.14, 11.60]	1.80
Hakanen et al, 2001	19	60	14	170		3.85 [ 1.82, 8.14]	2.85
Nicoletta Ansaldi et al, 2003	180	163	40	159		4.39 [ 2.92, 6.59]	4.05
Rosa Utiyama et al, 2005	8	68	4	93		2.74 [ 0.79, 9.45]	1.65
Selimog lu et al, 2005	17	60	2	38		5.38 [ 1.18, 24.63]	1.24
Guariso et al , 2007	23	244	1	98		- 9.24 [ 1.23, 69.34]	0.79
Elfstrom et al, 2008	144	13,877	191	67,877		3.69 [ 2.97, 4.58]	4.63
Naiyer et al, 2008	34	6	18	22		6.93 [ 2.38, 20.16]	2.00
Neuhausen et al, 2008	42	366	34	1,238		4.18 [ 2.62, 6.67]	3.84
Toumi et al, 2008	8	96	5	184		3.07 [ 0.98, 9.63]	1.83
A. Carlsson et al, 2009	13	194	31	1,120		2.42 [ 1.24, 4.71]	3.13
A. Meloni et al, 2009	34	290	235	7,805	-	3.89 [ 2.67, 5.68]	4.15
Erkan Caglar et al, 2009	3	28	4	25		0.67 [ 0.14, 3.29]	1.16
Garud et al, 2009	78	522	13	187		2.15 [ 1.17, 3.96]	3.32
Diamanti et al, 2011	56	489	51	571	-	1.28 [ 0.86, 1.91]	4.08
J. F. Ludvigsson, et al, 2011	315	7,528	187	38,779		8.68 [ 7.23, 10.42]	4.71
L Ban, 2014	99	1,781	12,142	548,310		2.51 [ 2.05, 3.08]	4.66
Nafeesa N, et al 2014	694	5,812	74,947	2,344,771		3.74 [ 3.45, 4.04]	4.87
Schuppan et al, 2014	55	46	40	92		2.75 [ 1.60, 4.72]	3.58
van der Pals et al, 2014	24	311	48	1,647		2.65 [ 1.60, 4.39]	3.70
Cristina Canova et al, 2016	59	1,156	60	6,015	-	5.12 [ 3.55, 7.37]	4.19
Stefano Bibbò et al, 2017	62	193	25	225		2.89 [ 1.75, 4.78]	3.71
Grode et al, 2018	393	3,778	2,408	41,366		1.79 [ 1.60, 2.00]	4.83
Grode et al, 2018	1,275	9,010	6,715	98,213		2.07 [ 1.94, 2.21]	4.88
Norström et al, 2018	21	288	47	1,618		2.51 [ 1.48, 4.26]	3.61
Khan et al, 2019	66	183	68	430	-	2.28 [ 1.56, 3.34]	4.14
Parastoo Baharvand et al, 2020	44	244	9	241		4.83 [ 2.31, 10.11]	2.89
Tiberti et al, 2020	11	81	24	213		1.21 [ 0.56, 2.57]	2.83
Overall					•	3.06 [ 2.51, 3.72]	

Heterogeneity:  $\tau^2 = 0.20$ ,  $I^2 = 92.66\%$ ,  $H^2 = 13.62$ Test of  $\theta_i = \theta_j$ : Q(30) = 408.59, p = 0.00 Test of  $\theta = 0$ : z = 11.19, p = 0.00

medRxiv preprint doi: https://doi.org/10.1101/2024.01.26.2	24301845; this version posted January 28, 2024.	The copyright holder for this preprint (which was not certified by	peer review) withe author/funder Weight
	Standard mad Ryiv	Also lay the preprint in perpetuity	

Study	4.01.20.2430164	who has grant It is mad	ted medRxiv a lited available under	copyright cense to display the pre er a CC-BY 4.0 Internat	print in perpetuity. onal license .	by peer review, perre authomatic	vveight
	res	INO	res	INO		with 95% CI	(%)
Case control study			40	454	-	0.057440 0.701	0.00
Sategna-Guidetti et al, 1998	38	147	19	151		2.05 [ 1.13, 3.73]	3.38
Velluzzi et al, 1998	14	33	9	82		3.87 [ 1.53, 9.79]	2.33
Kowalska et al, 2000	14	20	2	26		9.10 [ 1.85, 44.72]	1.16
Ventura et al, 2000	13	77	4	86		3.63 [ 1.14, 11.60]	1.80
Hakanen et al, 2001	19	60	14	170		3.85 [ 1.82, 8.14]	2.85
Nicoletta Ansaldi et al, 2003	180	163	40	159		4.39 [ 2.92, 6.59]	4.05
Rosa Utiyama et al, 2005	8	68	4	93		2.74 [ 0.79, 9.45]	1.65
Selimog lu et al, 2005	17	60	2	38		5.38 [ 1.18, 24.63]	1.24
Naiyer et al, 2008	34	6	18	22		6.93 [ 2.38, 20.16]	2.00
Neuhausen et al, 2008	42	366	34	1,238		4.18 [ 2.62, 6.67]	3.84
Toumi et al, 2008	8	96	5	184		3.07 [ 0.98, 9.63]	1.83
Garud et al, 2009	78	522	13	187		2.15 [ 1.17, 3.96]	3.32
Schuppan et al, 2014	55	46	40	92		2.75 [ 1.60, 4.72]	3.58
Stefano Bibbò et al, 2017	62	193	25	225		2.89 [ 1.75, 4.78]	3.71
Norström et al, 2018	21	288	47	1,618		2.51 [ 1.48, 4.26]	3.61
Tiberti et al, 2020	11	81	24	213		1.21 [ 0.56, 2.57]	2.83
Heterogeneity: $\tau^2 = 0.04$ , $I^2 = 23$ .	12%, H <sup>2</sup>	= 1.30			♦ :	3.09 [ 2.53, 3.79]	
Test of $\theta_i = \theta_j$ : Q(15) = 19.51, p =	= 0.19						
Cohort study							
Guariso et al, 2007	23	244	1	98		9.24 [ 1.23, 69.34]	0.79
Elfstrom et al, 2008	144	13,877	191	67,877		3.69 [ 2.97, 4.58]	4.63
A. Carlsson et al, 2009	13	194	31	1,120		2.42 [ 1.24, 4.71]	3.13
A. Meloni et al, 2009	34	290	235	7,805	-	3.89 [ 2.67, 5.68]	4.15
Diamanti et al, 2011	56	489	51	571	-	1.28 [ 0.86, 1.91]	4.08
J. F. Ludvigsson, et al, 2011	315	7,528	187	38,779		8.68 [ 7.23, 10.42]	4.71
L Ban, 2014	99	1,781	12,142	548,310		2.51 [ 2.05, 3.08]	4.66
Nafeesa N, et al 2014	694	5,812	74,947	2,344,771		3.74 [ 3.45, 4.04]	4.87
van der Pals et al, 2014	24	311	48	1,647		2.65 [ 1.60, 4.39]	3.70
Cristina Canova et al, 2016	59	1,156	60	6,015	-	5.12 [ 3.55, 7.37]	4.19
Heterogeneity: $\tau^2 = 0.20$ , $I^2 = 93$ .	08%, H <sup>2</sup>	= 14.46			♦ :	3.48 [ 2.55, 4.76]	
Test of $\theta_i = \theta_j$ : Q(9) = 130.12, p =	= 0.00						
Cross sectional Study							
Erkan Caglar et al, 2009	3	28	4	25		0.67 [ 0.14, 3.29]	1.16
Grode et al, 2018	393	3,778	2,408	41,366		1.79 [ 1.60, 2.00]	4.83

51000 Ct al, 2010 000 0,110 2,100 ...,000 1,275 9,010 6,715 Grode et al, 2018 98,213 Khan et al, 2019 66 183 68 430 Parastoo Baharvand et al, 2020 44 244 9 241 Heterogeneity:  $\tau^2 = 0.02$ ,  $I^2 = 68.59\%$ ,  $H^2 = 3.18$ Test of  $\theta_i = \theta_j$ : Q(4) = 12.73, p = 0.01


Overall


Heterogeneity:  $\tau^2 = 0.20$ ,  $I^2 = 92.66\%$ ,  $H^2 = 13.62$ 

Test of  $\theta_i = \theta_j$ : Q(30) = 408.59, p = 0.00

Test of group differences:  $Q_b(2) = 13.94$ , p = 0.00

Random-effects DerSimonian–Laird model Sorted by: Year







medRxiv preprint doi: https://doi.org/10.1101			as granted med It is made avail	able under a CC-BY 4	.0 International license .	with 95% Cl	
Study	Yes	No	res	INO		with 95% CI	(%)
Poor		40.077		07 077	_		
Elfstrom et al, 2008	144	13,877	191	67,877	_	3.69 [ 2.97, 4.58]	4.63
Garud et al, 2009	78	522	13	187	-	2.15 [ 1.17, 3.96]	3.32
L Ban, 2014	99	1,781	12,142	548,310		2.51 [ 2.05, 3.08]	4.66
Nafeesa N, et al 2014	694	5,812	74,947	2,344,771		3.74 [ 3.45, 4.04]	4.87
Parastoo Baharvand et al, 2020	44	244	9	241		4.83 [ 2.31, 10.11]	2.89
Schuppan et al, 2014	55	46	40	92	-	2.75 [ 1.60, 4.72]	3.58
Tiberti et al, 2020	11	81	24	213		1.21 [ 0.56, 2.57]	2.83
Heterogeneity: $\tau^2 = 0.05$ , $I^2 = 75.6$	57%, H <sup>2</sup>	= 4.11			•	2.98 [ 2.37, 3.74]	
Test of $\theta_i = \theta_j$ : Q(6) = 24.66, p = 0	0.00						
Good					_		
A. Carlsson et al, 2009	13	194	31	1,120		2.42 [ 1.24, 4.71]	3.13
A. Meloni et al, 2009	34	290	235	7,805	-	3.89 [ 2.67, 5.68]	4.15
Cristina Canova et al, 2016	59	1,156	60	6,015	-	5.12 [ 3.55, 7.37]	4.19
Diamanti et al, 2011	56	489	51	571	-	1.28 [ 0.86, 1.91]	4.08
Erkan Caglar et al, 2009	3	28	4	25		0.67 [ 0.14, 3.29]	1.16
Grode et al, 2018	393	3,778	2,408	41,366		1.79 [ 1.60, 2.00]	4.83
Grode et al, 2018	1,275	9,010	6,715	98,213		2.07 [ 1.94, 2.21]	4.88
Guariso et al , 2007	23	244	1	98		9.24 [ 1.23, 69.34]	0.79
Hakanen et al, 2001	19	60	14	170		3.85 [ 1.82, 8.14]	2.85
Khan et al, 2019	66	183	68	430	-	2.28 [ 1.56, 3.34]	4.14
Kowalska et al, 2000	14	20	2	26		9.10 [ 1.85, 44.72]	1.16
Naiyer et al, 2008	34	6	18	22		6.93 [ 2.38, 20.16]	2.00
Nicoletta Ansaldi et al, 2003	180	163	40	159	-	4.39 [ 2.92, 6.59]	4.05
Norström et al, 2018	21	288	47	1,618		2.51 [ 1.48, 4.26]	3.61
Sategna-Guidetti et al, 1998	38	147	19	151		2.05 [ 1.13, 3.73]	3.38
Selimog lu et al, 2005	17	60	2	38		5.38 [ 1.18, 24.63]	1.24
Stefano Bibbò et al, 2017	62	193	25	225		2.89 [ 1.75, 4.78]	3.71
Toumi et al, 2008	8	96	5	184	_	3.07 [ 0.98, 9.63]	1.83
van der Pals et al, 2014	24	311	48	1,647		2.65 [ 1.60, 4.39]	3.70
Velluzzi et al, 1998	14	33	9	82		3.87 [ 1.53, 9.79]	2.33
Ventura et al, 2000	13	77	4	86		3.63 [ 1.14, 11.60]	1.80
Heterogeneity: $\tau^2 = 0.08$ , $I^2 = 75.5$	58%, H <sup>2</sup>	= 4.10			•	2.76 [ 2.31, 3.30]	
					*		

38,779

1,238

93

Test of  $\theta_i = \theta_j$ : Q(20) = 81.91, p = 0.00

J. F. Ludvigsson, et al, 2011 7,528 187 315 Neuhausen et al, 2008 42 366 34 Rosa Utiyama et al, 2005 8 68 4 Heterogeneity:  $\tau^2 = 0.26$ ,  $I^2 = 81.65\%$ ,  $H^2 = 5.45$ Test of  $\theta_i = \theta_j$ : Q(2) = 10.90, p = 0.00


## Overall

Heterogeneity:  $\tau^2 = 0.20$ ,  $I^2 = 92.66\%$ ,  $H^2 = 13.62$ 

Test of  $\theta_i = \theta_j$ : Q(30) = 408.59, p = 0.00


Test of group differences:  $Q_b(2) = 3.57$ , p = 0.17

Random-effects DerSimonian-Laird model Sorted by: NOS\_1



8.68 [ 7.23, 10.42] 4.71 4.18 [ 2.62, 6.67] 3.84 2.74 [ 0.79, 9.45] 1.65 5.36 [ 2.74, 10.49]

3.06 [ 2.51, 3.72]



	C	ase	Co	ntrol		OR	Weight
Study	Yes	No	Yes	No		with 95% CI	(%)
Autoimmune							
Sategna-Guidetti et al, 1998	38	147	19	151		2.05 [ 1.13, 3.73]	3.38
Velluzzi et al, 1998	14	33	9	82		3.87 [ 1.53, 9.79]	2.33
Kowalska et al, 2000	14	20	2	26		9.10 [ 1.85, 44.72]	1.16
Ventura et al, 2000	13	77	4	86		3.63 [ 1.14, 11.60]	1.80
Hakanen et al, 2001	19	60	14	170		3.85 [ 1.82, 8.14]	2.85
Nicoletta Ansaldi et al, 2003	180	163	40	159	-	4.39 [ 2.92, 6.59]	4.05
Rosa Utiyama et al, 2005	8	68	4	93		2.74 [0.79, 9.45]	1.65
Guariso et al , 2007	23	244	1	98		- 9.24 [ 1.23, 69.34]	0.79
Naiyer et al, 2008	34	6	18	22		6.93 [2.38, 20.16]	2.00
Toumi et al, 2008	8	96	5	184		3.07 [ 0.98, 9.63]	1.83
A. Carlsson et al, 2009	13	194	31	1,120		2.42 [ 1.24, 4.71]	3.13
A. Meloni et al, 2009	34	290	235	7,805	-	3.89 [2.67, 5.68]	4.15
Erkan Caglar et al, 2009	3	28	4	25 -		0.67 [ 0.14, 3.29]	1.16
Garud et al, 2009	78	522	13	187		2.15 [ 1.17, 3.96]	3.32
Diamanti et al, 2011	56	489	51	571	-	1.28 [ 0.86, 1.91]	4.08
J. F. Ludvigsson, et al, 2011	315	7,528	187	38,779		8.68 [7.23, 10.42]	4.71
Schuppan et al, 2014	55	46	40	92		2.75 [ 1.60, 4.72]	3.58
van der Pals et al, 2014	24	311	48	1,647		2.65 [ 1.60, 4.39]	3.70
Cristina Canova et al, 2016	59	1,156	60	6,015	-	5.12 [ 3.55, 7.37]	4.19
Stefano Bibbò et al, 2017	62	193	25	225		2.89 [ 1.75, 4.78]	3.71
Grode et al, 2018	393	3,778	2,408	41,366		1.79 [ 1.60, 2.00]	4.83
Grode et al, 2018	1,275	9,010	6,715	98,213		2.07 [ 1.94, 2.21]	4.88
Norström et al, 2018	21	288	47	1,618		2.51 [ 1.48, 4.26]	3.61
Khan et al, 2019	66	183	68	430	-	2.28 [ 1.56, 3.34]	4.14
Parastoo Baharvand et al, 2020	44	244	9	241		4.83 [2.31, 10.11]	2.89
Tiberti et al, 2020	11	81	24	213		1.21 [ 0.56, 2.57]	2.83
Heterogeneity: $\tau^2 = 0.27$ , $I^2 = 91.6$	6%, H <sup>2</sup>	= 12.00			٠	2.96 [ 2.32, 3.78]	
Test of $\theta_i = \theta_j$ : Q(25) = 299.89, p =	= 0.00						
Thyroid Disorders							
Selimog lu et al, 2005	17	60	2	38		5.38 [ 1.18, 24.63]	1.24
Elfstrom et al, 2008	144	13,877	191	67,877		3.69 [ 2.97, 4.58]	4.63
Neuhausen et al, 2008	42	366	34	1,238		4.18 [ 2.62, 6.67]	3.84


L Ban, 2014 99 1,781 12,142 548,310 Nafeesa N, et al 2014 694 5,812 74,947 2,344,771 Heterogeneity:  $\tau^2 = 0.03$ ,  $I^2 = 70.61\%$ ,  $H^2 = 3.40$ Test of  $\theta_i = \theta_j$ : Q(4) = 13.61, p = 0.01

## Overall


Heterogeneity:  $\tau^2 = 0.20$ ,  $I^2 = 92.66\%$ ,  $H^2 = 13.62$ Test of  $\theta_i = \theta_j$ : Q(30) = 408.59, p = 0.00

Test of group differences:  $Q_b(1) = 0.79$ , p = 0.37

Random-effects DerSimonian–Laird model Sorted by: Year




## 3.06 [ 2.51, 3.72]



who h	rersion posted January 28, 2024. The copyright holder for this preprint <b>(which wa</b> as granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.	as not certified by peer review) is the author/fun	der,
Omitted study		with 95% CI	p-value
A. Carlsson et al, 2009		3.08 [ 2.52, 3.76]	0.000
A. Meloni et al, 2009	•	3.03 [ 2.48, 3.70]	0.000
Cristina Canova et al, 2016		2.99 [ 2.45, 3.65]	0.000
Diamanti et al, 2011	•	- 3.17 [ 2.60, 3.87]	0.000
Elfstrom et al, 2008		3.03 [ 2.47, 3.72]	0.000
Erkan Caglar et al, 2009	•	3.11 [ 2.56, 3.79]	0.000
Garud et al, 2009	•	3.10 [ 2.54, 3.78]	0.000
Grode et al, 2018	•	- 3.14 [ 2.57, 3.85]	0.000
Grode et al, 2018	•	- 3.12 [ 2.53, 3.86]	0.000
Guariso et al, 2007		3.03 [ 2.49, 3.69]	0.000
Hakanen et al, 2001		3.04 [ 2.49, 3.71]	0.000
J. F. Ludvigsson, et al, 2011		2.88 [ 2.43, 3.41]	0.000
Khan et al, 2019	•	3.10 [ 2.53, 3.79]	0.000
Kowalska et al, 2000	•	3.02 [ 2.48, 3.68]	0.000
L Ban, 2014	•	3.09 [ 2.52, 3.79]	0.000
Nafeesa N, et al 2014		3.03 [ 2.45, 3.75]	0.000
Naiyer et al, 2008	•	3.01 [ 2.47, 3.67]	0.000
Neuhausen et al, 2008	•	3.02 [ 2.47, 3.69]	0.000
Nicoletta Ansaldi et al, 2003	•	3.01 [ 2.47, 3.68]	0.000
Norström et al, 2018		3.08 [ 2.52, 3.77]	0.000
Parastoo Baharvand et al, 2020	•	3.02 [ 2.47, 3.68]	0.000
Rosa Utiyama et al, 2005		3.07 [ 2.51, 3.74]	0.000
Sategna-Guidetti et al, 1998	•	3.10 [ 2.54, 3.79]	0.000
Schuppan et al, 2014		3.07 [ 2.51, 3.75]	0.000
Selimog lu et al, 2005	•	3.04 [ 2.49, 3.70]	0.000



Ventura et al, 2000



0.000

0.000


0.000

0.000

0.000

0.000

Random-effects DerSimonian-Laird model



# Figure